Stavros G. Vizirgianakis - 29 Oct 2021 Form 4 Insider Report for Bioventus Inc. (BVS)

Role: Director
Signature: /s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol: BVS
Transactions as of: 29 Oct 2021
Transactions value $: $0
Form type: 4
Filing time: 28 Apr 2022, 16:24:44 UTC
Previous filing: 02 Jul 2021
Next filing: 22 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BVS	Class A Common Stock	Award		+2.78M			2.78M	29 Oct 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each share of Misonix Inc. ("Misonix") common stock (a "Misonix Option") that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of the Company's Class A Common Stock, $0.001 par value per share ("Bioventus Shares"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

Content

Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each share of Misonix Inc. ("Misonix") common stock (a "Misonix Option") that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of the Company's Class A Common Stock, $0.001 par value per share ("Bioventus Shares"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.